-+ 0.00%
-+ 0.00%
-+ 0.00%

VERRICA PHARMACEUTICALS ANNOUNCES FIRST U.S. PATIENT DOSED IN THE SECOND PIVOTAL CLINICAL TRIAL (COVE-3) OF ITS PHASE 3 PROGRAM EVALUATING YCANTH® (VP-102) FOR THE TREATMENT OF COMMON WARTS

Reuters·06/22/2026 12:05:00

Please log in to view news